<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02083250</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0999</org_study_id>
    <secondary_id>NCI-2014-01982</secondary_id>
    <secondary_id>2012-0999</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02083250</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant</brief_title>
  <official_title>Fludarabine/Clofarabine/Busulfan Combined With SAHA in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of vorinostat when given together&#xD;
      with fludarabine phosphate, clofarabine, and busulfan in treating patients with acute&#xD;
      leukemia that is under control (remission) or has returned (relapse) undergoing donor stem&#xD;
      cell transplant. Vorinostat may stop the growth of cancer cells by blocking some of the&#xD;
      enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate,&#xD;
      clofarabine, and busulfan, work in different ways to stop the growth of cancer cells, either&#xD;
      by killing the cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
      Giving vorinostat together with fludarabine phosphate, clofarabine, and busulfan before a&#xD;
      donor stem cell transplant may be a better treatment for patients with acute leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of SAHA (vorinostat) in combination with the&#xD;
      preparative regimen fludarabine (fludarabine phosphate), clofarabine, and busulfan followed&#xD;
      by allogeneic hematopoietic stem cell transplantation (SCT) for patients with advanced acute&#xD;
      leukemia.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the rate of graft versus host disease (GVHD), engraftment, progression-free&#xD;
      survival (PFS) and overall survival (OS) for this treatment regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of vorinostat.&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive vorinostat orally (PO) once daily (QD), fludarabine&#xD;
      phosphate intravenously (IV) over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3&#xD;
      hours on days -6 to -3. Patients receiving a transplant from a human leukocyte antigen&#xD;
      (HLA)-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to&#xD;
      -1.&#xD;
&#xD;
      TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant&#xD;
      on day 0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 6, 2014</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of vorinostat when given in combination with fludarabine phosphate, clofarabine, and busulfan before stem cell transplant assessed using Common Terminology Criteria for Adverse Events version 4</measure>
    <time_frame>30 days</time_frame>
    <description>The 2-stage time-to-event continual reassessment method will be used. Toxicity will be tabulated by dose, type, and grade. The probability of toxicity over 30 days as a function of dose will be estimated by fitting a Bayesian binary outcome regression model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be estimated by the Kaplan and Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be estimated by the Kaplan and Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation Recipient</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <condition>Recurrent Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive vorinostat PO QD, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -6 to -3. Patients receiving a transplant from a HLA-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to -1.&#xD;
TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell or bone marrow transplant</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell or bone marrow transplant</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic peripheral blood stem cell or bone marrow transplant</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (vorinostat, chemotherapy, SCT)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>MSK-390</other_name>
    <other_name>SAHA</other_name>
    <other_name>Suberanilohydroxamic Acid</other_name>
    <other_name>Suberoylanilide Hydroxamic Acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with biopsy-proven acute lymphoblastic leukemia, acute myeloid leukemia, or&#xD;
             myelodysplastic syndrome in remission or relapse&#xD;
&#xD;
          -  Estimated creatinine clearance at least 50 ml/min&#xD;
&#xD;
          -  Bilirubin equal or less than 1.5 (unless Gilbert's syndrome)&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) &lt; 3 x upper limit of normal&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 x upper limit of normal&#xD;
&#xD;
          -  Pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital&#xD;
             capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) at least&#xD;
             45% of expected corrected for hemoglobin; children unable to perform pulmonary&#xD;
             functions must have an oxygen saturation greater than 92% at room air&#xD;
&#xD;
          -  Left ventricular ejection fraction at least 45% on appropriate medical therapy; no&#xD;
             uncontrolled arrhythmias or symptomatic cardiac disease&#xD;
&#xD;
          -  Zubrod performance status 0-1 or Lansky/Karnofsky performance status (PS) equal or&#xD;
             greater to 80%&#xD;
&#xD;
          -  Patients must have a related, genotypically HLA identical donor, or they must have an&#xD;
             unrelated donor who is 8/8 HLA match by high resolution typing&#xD;
&#xD;
          -  Patient or patient's legal representative, parent(s) or guardian should provide&#xD;
             written informed consent; assent of a minor if participant's age is at least seven and&#xD;
             less than eighteen years&#xD;
&#xD;
          -  Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing&#xD;
             potential defined as not post-menopausal for 12 months and no previous surgical&#xD;
             sterilization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active central nervous system (CNS) disease&#xD;
&#xD;
          -  Evidence of acute or chronic active hepatitis or cirrhosis&#xD;
&#xD;
          -  Uncontrolled infection, including human immunodeficiency virus (HIV), human&#xD;
             T-lymphotropic virus (HTLV)-1, hepatitis B or hepatitis C viremia&#xD;
&#xD;
          -  Prior allogeneic SCT&#xD;
&#xD;
          -  Prior autologous SCT in last 12 months&#xD;
&#xD;
          -  Patients with acute myeloid leukemia (AML) in first remission after one course of&#xD;
             induction and with favorable cytogenetics (t[8;21], inv 16, or t[15;17]) and/or&#xD;
             molecular profile (nucleophosmin [NPM]1)&#xD;
&#xD;
          -  Prior radiation to liver in form of total body or involved field&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Partow Kebriaei</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

